We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions around Oxford Biomedica Plc (OXB) have been marked by mixed sentiments as the year draws to a close. While some investors express frustration over the stock's underperformance, particularly regarding its potential for re-entry into the FTSE250, others remain hopeful for a turnaround in 2025. Notably, harry s truman highlighted the company's forecasted financial guidance, stating, "the next year we enter a week tomorrow is guided at C£180m and a profit which is not a small cap stock," indicating a belief in fundamental value not yet reflected in the market capitalization.
Despite some volatility in stock performance throughout the week, as dominiccummings pointed out, "Down heavily at 14:00, then straight up again," there seems to be cautious optimism among longer-term holders. Jasierock conveyed a sense of mounting frustration due to the slow progress, but echoed sentiments of resilience in the face of challenges. As the community welcomes 2025, gutterhead’s comment, "2025 could be the year…" encapsulates the prevailing hope that the company's prospects may improve significantly in the coming year, possibly rekindling investor confidence. Overall, the discussions reflect a blend of caution and optimism, as investors keenly watch for signs of recovery.
Show more
Oxford Biomedica Plc (OXB), a prominent contract development and manufacturing organization specializing in cell and gene therapy, has announced several noteworthy developments over recent weeks. As of December 2, 2024, the company's total voting rights amounted to 105,938,933 ordinary shares. This information is crucial for shareholders when determining their notification obligations under the UK's FCA regulations. In line with their ongoing commitment to corporate governance, OXB also made management changes, most notably the appointment of Colin Bond as a Non-Executive Director effective from January 1, 2025, bolstering the board with extensive industry experience.
On the financial front, OXB has been active in initiating long-term incentive plans, recently granting options under its 2024 Long Term Incentive Plan to key personnel, such as Mark Caswell, Site Head of UK Operations. Additionally, the company is enhancing its market presence through initiatives like hosting a free webinar on accelerating viral vector manufacturing, highlighting its expertise in automated processes. Oxford Biomedica also presented at the Jefferies London Healthcare Conference on November 19, indicating its proactive approach in engaging with the investor community and promoting its innovations within the cell and gene therapy landscape.
Show more
With one board member placed there by Novo, at least a core of the board are involved, else how could they embargo insider investment? |
First thread "deerstalker and pipe" award of the year to Phil. |
Conclusion: Inappropriate or Strategic Silence? |
Whoah! AI agrees a buyout is on the cards. |
This is chat gpt output from the various points I have given it about oxb’s 35% CAGR forecast over next three years, price being potentially held and the Novo/Catalent deal with Novo being in our board:- |
Let me guess. Down to , oh, say 415 by 2:00pm, up to 420 by close. |
Re 9449 - not oxb related |
I'm pretty sure there is some sort of protection for someone with less than 25%, who would be an 'Oppressed shareholder'. May be worth looking up that term? |
W5AMH, |
Oh. Goodness me! It looks like we are going to finish at the opening price again.... |
Not OXB RELATED…. |
One would think the market was still closed given the volume traded this morning ! |
Gone but not forgotten Gareth. |
The Chinese New Year begins on 29th January, the year of the wood snake. A time of transformation, growth and introspection. Happy New Year to all Chinese and other nationalities Worldwide. |
Admittedly I have the gift of being able to curse things with a sweeping statement, but this should be the last of our odd volume / trade silly season days before normal service is returned on Thursday. |
posting primarily to get notifications, but following Brucie here from ONT. |
How strange. Down heavily at 14:00, then straight up again, after which the 'up guy' gets bored and lets it be dropped to the 420's where it finishes. |
You know my thoughts Jasie and that I've been angling for OXB's return to the FTSE250 all year. |
I haven't posted much on here this year possibly born out of frustration at the stubborn progress. For the vast majority of the very long time i have held this stock it has been like wading through treacle with the odd stellar spell when the sensible would have 'banked' I'm still frustrated by the lack of news and information but I decided long ago to see this through to the end. I doubt we will see £15 again but you never know!! |
Compliments of the season to all here. |
Clearly being manipulated by people in the know. Mutters of that doesn't go on in the squeeky clean LSE. Oh yes it does! |
Isn't it remarkable how the share price seems to start and end pretty much the same whether it goes up or down during the day? |
Happy Christmas all. |
Time to wind down for festive season, enjoy, hopefully the New Year will bring an end to this large (ish) volume, small trade pattern. The futures bright the futures OXB? Tempus revelat omni. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 422.00 |
Offer Price | 423.50 |
Open | 420.00 |
Shares Traded | 70,466 |
Last Trade | 16:35:05 |
Low - High | 419.50 - 425.00 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.42 |
Market Cap | 442.51M |
In a bid to push back northward in the activities that have been relatively prevailing in the exchange market of Eden Research Plc (LSE:EDEN), the stock operation now holds a consolidation, tending to increase potentially through the barriers of 4. Technically speaking, it has been demonstrated that the crucial trade zones that the buyers...
Continue Reading
Relatively, there has been a depression movement to plummet a considerable hike in the operations of Boohoo Group Plc (LSE:BOO), given that the stock trade is in an upward momentum, keeping a basis closely to the 32 value line. In the event that the market eventually intensifies and continues to run further downward in the […]
Continue Reading
The price actions being demonstrated in the operations of Plexus Holdings Plc (LSE:POS) showcase that the stock market slightly retraces, forming a basis around 10. In the long-term pushing pattern, the reversal mode’s intensity rate often exits the market in a range of values around 10 and 9. Investors are advised to strengthen the...
Continue Reading
Using cryptocurrency for non gamstop casinos on bideford.com has reshaped the industry. This innovation offers unique benefits aligned with modern player needs. Essential features like fast transactions make digital currencies an appealing alternative to traditional payment methods in casinos. This article examines the impact of using cry...
Continue Reading
Solana’s decentralized applications (dapps) experienced a surge in revenue during November, with the ecosystem collectively generating a record-breaking sum. Notably, Pumpfun, a prominent player within the Solana ecosystem, surpassed the $100 million revenue milestone, showcasing the growing maturity and profitability of the Solana ...
Continue Reading
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads